PCM
MGNX icon

Prelude Capital Management’s MacroGenics MGNX Stock Holding History

Prelude Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$6K – 2162
2020
Q2 		$6K Buy
+200
New +$3.47K ﹤0.01% 1680

Other funds holding MGNX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Prelude Capital Management's MGNX Position: Q2 2026 in Review

Prelude Capital Management opened a new position in MacroGenics (MGNX) in Q2 2026: 26,300 shares worth $122K. The stake represents 0.01% of the portfolio and ranks #1085 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in MGNX as recently as Q2 2024.

Prelude Capital Management first reported a position in MGNX in Q4 2014 and has held it in 21 quarters since. The position peaked at $291K in Q4 2023. 122 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

  • Prelude Capital Management held 26,300 shares of MacroGenics worth $122K as of Q2 2026.
  • MacroGenics was a new Prelude Capital Management position in Q2 2026.
  • MacroGenics made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1085 holding.
  • Prelude Capital Management first reported a position in MacroGenics in Q4 2014 and has held it in 21 quarters since.
  • Prelude Capital Management's MacroGenics position peaked at $291K in Q4 2023.
  • 122 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.